Reply to the letter to the editor from Oudejans et al

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2515-

  Chang, Kung Chao ^a   Jones, Dan ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B;

B CELL LYMPHOMA; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; ENZYME BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 42249106215     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5178     Document Type: Letter

References (7)

1. Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and Tcells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007;13:6666-72.
2. Muris JJ, Meijer CJ, Cillessen SA, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004;18:589-96.
3. Riemersma SA, Oudejans JJ, Vonk MJ, et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 2005;206:328-36.
4. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007;137:364-73.
5. Lippman SM, Spier CM, Miller TP, Slymen DJ, Rybski JA, Grogan TM. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990;3:361-7.
6. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study fromt he Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251-8.
7. Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 2004;9:577-86.